Baidu
map

Oncogene:外泌体介导的lncRUNX2-AS1有助于成骨

2018-06-15 MedSci MedSci原创

多发性骨髓瘤(MM)的特征是间充质干细胞(MSCs)的成骨能力降低。癌细胞和癌症基质细胞之间的交流是肿瘤进展的主要因素。了解骨髓瘤-基质的相互作用对于开发可逆转骨疾病的有效策略至关重要。本研究中,我们发现骨髓瘤细胞中的生物活性lncRNA RUNX2-AS1可以包装到外泌体中并传递给MSCs,从而抑制MSCs的成骨。来自RUNX2反义链的RUNX2-AS1在源自MM患者(MM-MSC)的MSCs中

多发性骨髓瘤(MM)的特征是间充质干细胞(MSCs)的成骨能力降低。癌细胞和癌症基质细胞之间的交流是肿瘤进展的主要因素。了解骨髓瘤-基质的相互作用对于开发可逆转骨疾病的有效策略至关重要。

本研究中,我们发现骨髓瘤细胞中的生物活性lncRNA RUNX2-AS1可以包装到外泌体中并传递给MSCs,从而抑制MSCs的成骨。来自RUNX2反义链的RUNX2-AS1在源自MM患者(MM-MSC)的MSCs中富集。RUNX2-AS1能够在重叠区域与RUNX2前体mRNA形成RNA双链体,并且该双链体通过降低剪接效率而转录地抑制RUNX2表达,从而导致MSCs的成骨潜能下降。小鼠模型中使用外泌体分泌抑制剂GW4869可有效预防由骨形成和抗代谢活性所制的骨丢失。因此,外泌体lncRNA RUNX2-AS1可能成为MM骨病变的潜在治疗靶点。

总之,该研究结果表明,外源性lncRUNX2-AS1通过特定的外泌体lncRUNX2-AS1/RUNX2通路在成骨分化中从MM细胞向MSCs转移中发挥关键作用。

原始出处:

Li B, Xu H, et al. Exosome-mediated transfer of lncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis. Oncogene. 2018 Jun 12. doi: 10.1038/s41388-018-0359-0.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049041, encodeId=11e12049041b5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Mar 27 23:26:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669006, encodeId=9f4f166900631, content=<a href='/topic/show?id=f4c915e4262' target=_blank style='color:#2F92EE;'>#Runx2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15742, encryptionId=f4c915e4262, topicName=Runx2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635226492904, createdName=stfoxst, createdTime=Mon Jul 16 01:26:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351728, encodeId=16ea1351e2882, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 17 11:26:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558119, encodeId=12dc15581196d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Jun 17 11:26:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324663, encodeId=3fca32466365, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 16 13:43:35 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324470, encodeId=3aec3244e05d, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Jun 15 22:35:36 CST 2018, time=2018-06-15, status=1, ipAttribution=)]
    2019-03-27 heli0118
  2. [GetPortalCommentsPageByObjectIdResponse(id=2049041, encodeId=11e12049041b5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Mar 27 23:26:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669006, encodeId=9f4f166900631, content=<a href='/topic/show?id=f4c915e4262' target=_blank style='color:#2F92EE;'>#Runx2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15742, encryptionId=f4c915e4262, topicName=Runx2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635226492904, createdName=stfoxst, createdTime=Mon Jul 16 01:26:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351728, encodeId=16ea1351e2882, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 17 11:26:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558119, encodeId=12dc15581196d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Jun 17 11:26:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324663, encodeId=3fca32466365, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 16 13:43:35 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324470, encodeId=3aec3244e05d, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Jun 15 22:35:36 CST 2018, time=2018-06-15, status=1, ipAttribution=)]
    2018-07-16 stfoxst
  3. [GetPortalCommentsPageByObjectIdResponse(id=2049041, encodeId=11e12049041b5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Mar 27 23:26:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669006, encodeId=9f4f166900631, content=<a href='/topic/show?id=f4c915e4262' target=_blank style='color:#2F92EE;'>#Runx2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15742, encryptionId=f4c915e4262, topicName=Runx2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635226492904, createdName=stfoxst, createdTime=Mon Jul 16 01:26:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351728, encodeId=16ea1351e2882, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 17 11:26:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558119, encodeId=12dc15581196d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Jun 17 11:26:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324663, encodeId=3fca32466365, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 16 13:43:35 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324470, encodeId=3aec3244e05d, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Jun 15 22:35:36 CST 2018, time=2018-06-15, status=1, ipAttribution=)]
    2018-06-17 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=2049041, encodeId=11e12049041b5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Mar 27 23:26:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669006, encodeId=9f4f166900631, content=<a href='/topic/show?id=f4c915e4262' target=_blank style='color:#2F92EE;'>#Runx2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15742, encryptionId=f4c915e4262, topicName=Runx2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635226492904, createdName=stfoxst, createdTime=Mon Jul 16 01:26:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351728, encodeId=16ea1351e2882, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 17 11:26:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558119, encodeId=12dc15581196d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Jun 17 11:26:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324663, encodeId=3fca32466365, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 16 13:43:35 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324470, encodeId=3aec3244e05d, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Jun 15 22:35:36 CST 2018, time=2018-06-15, status=1, ipAttribution=)]
    2018-06-17 zsyan
  5. [GetPortalCommentsPageByObjectIdResponse(id=2049041, encodeId=11e12049041b5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Mar 27 23:26:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669006, encodeId=9f4f166900631, content=<a href='/topic/show?id=f4c915e4262' target=_blank style='color:#2F92EE;'>#Runx2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15742, encryptionId=f4c915e4262, topicName=Runx2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635226492904, createdName=stfoxst, createdTime=Mon Jul 16 01:26:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351728, encodeId=16ea1351e2882, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 17 11:26:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558119, encodeId=12dc15581196d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Jun 17 11:26:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324663, encodeId=3fca32466365, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 16 13:43:35 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324470, encodeId=3aec3244e05d, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Jun 15 22:35:36 CST 2018, time=2018-06-15, status=1, ipAttribution=)]
    2018-06-16 kafei

    学习了谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2049041, encodeId=11e12049041b5, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Mar 27 23:26:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669006, encodeId=9f4f166900631, content=<a href='/topic/show?id=f4c915e4262' target=_blank style='color:#2F92EE;'>#Runx2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15742, encryptionId=f4c915e4262, topicName=Runx2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635226492904, createdName=stfoxst, createdTime=Mon Jul 16 01:26:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351728, encodeId=16ea1351e2882, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 17 11:26:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558119, encodeId=12dc15581196d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Jun 17 11:26:00 CST 2018, time=2018-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324663, encodeId=3fca32466365, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jun 16 13:43:35 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324470, encodeId=3aec3244e05d, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Jun 15 22:35:36 CST 2018, time=2018-06-15, status=1, ipAttribution=)]
    2018-06-15 1e1b8538m79(暂无匿称)

    不错的文章值得拥有哦

    0

相关资讯

Nanomaterials (Basel):基于纸的微流体平台发现外泌体在引起失明的疾病中具有致病作用

台湾台中市中山医科大学附属医院眼科的Hsu MY最近在Nanomaterials (Basel)发表了一篇文章,他们通过对房水进行分析,发现在主要导致失明的威胁性疾病如年龄相关性黄斑变性、青光眼和角膜营养不良中,外泌体具有致病作用。

Cell Death Dis:发现肿瘤相关巨噬细胞促进胃癌转移新机制

近日,来自上海交通大学医学院附属新华医院检验科沈立松课题组的研究人员在胃癌的发病机制方面取得了新的进展,明确了肿瘤相关巨噬细胞来源的外泌体对胃癌转移的影响,发现M2型巨噬细胞亚群通过外泌体传递ApoE蛋白分子促进胃癌细胞的迁移及转移过程。该成果发表在最新一期的Cell Death & Disease 杂志上。

2018(第三届)外泌体与疾病研讨会在沪举行,盛况空前!

3月23日--24日,2018(第三届)外泌体与疾病研讨会于上海盛大召开,大会围绕外泌体的基础研究、临床应用和相关分离检测技术等议题展开学术交流。会议期间,各参会嘉宾专家分享外泌体前沿科技成果、解析外泌体研究的最新技术,吸引了海内外行业同仁的高度关注,会议现场座无虚席! 本届研讨会在前两届会议的基础上,大刀阔斧全面升级,广邀专家学者以及青年学者进行学术交流,促进科研转化。会议集中体现近年来国

Adv Funct Mater:功能化外泌体将光热治疗与化疗结合高效靶向治疗癌症

近期,国际权威学术期刊《Advanced Functional Materials》发表了华中科技大学刘笔锋教授团队的重要研究成果,题为“Designer Exosomes for Active Targeted Chemo Photothermal Synergistic Tumor Therapy”。

Hypertension:外泌体及其含有的Y RNA片段可减轻AngII诱导的终末器官损伤

高血压常导致心血管疾病和肾功能异常。心内膜源细胞的外泌体(CDC-exo)及其最组成最丰富的小RNA——Y RNA片段EC-YF1,在心肌梗死后发挥治疗作用。Linda Cambier等研究人员在长期注射血管紧张素II(Ang-II)诱导的心肌肥大和肾损伤模型中研究CDC-exo和EC-YF1的作用。经过2周的AngII处理后,多次予以CDC-exo或EV-FY1治疗。结果发现,AngII诱导的收

Diabetes:血浆外泌体可通过激活经典补体信号通路促进糖尿病视网膜病变的微血管损伤

糖尿病视网膜病变(DR)是糖尿病的微血管并发症,是劳动年龄的成年人视力下降的主要原因。近期有研究表明补体系统在血管损伤发展和DR进展中也发挥一定作用。但是,补体系统激活在DR中的作用尚不是十分明确。外泌体,分泌到细胞外环境的小囊泡,在血浆中含有大量补体蛋白,提示其可能参与导致与DR相关的血管损伤。研究人员证实血浆中充满IgG的外泌体可激活经典补体通路,而在糖尿病患者血浆中,这类外泌体量增多。而且,

Baidu
map
Baidu
map
Baidu
map